TScan Therapeutics, Inc. Profile Avatar - Palmy Investing

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic m…

Biotechnology
US, Waltham [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of TCRX's Analysis
CIK: 1783328 CUSIP: 89854M101 ISIN: US89854M1018 LEI: - UEI: -
Secondary Listings
TCRX has no secondary listings inside our databases.